Aequus Pharmaceuticals (FRA:AEQ) LT-Debt-to-Total-Asset : 0.57 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Aequus Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aequus Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.57.

Aequus Pharmaceuticals's long-term debt to total assets ratio increased from Sep. 2023 (0.52) to Sep. 2024 (0.57). It may suggest that Aequus Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Aequus Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Aequus Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals LT-Debt-to-Total-Asset Chart

Aequus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

1.24

0.69

0.02

0.41

0.54

Aequus Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.52	0.54	0.51	0.52	0.57

Aequus Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Aequus Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.399	/	0.742
	=	0.54

Aequus Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	0.327	/	0.571
	=	0.57

Aequus Pharmaceuticals (FRA:AEQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aequus Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aequus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (FRA:AEQ) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

AQSZF:USA AQS:Canada

Address

200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4

Website

https://www.aequuspharma.ca

Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.

Aequus Pharmaceuticals Headlines

No Headlines